Xiamen Hengxing Group Co., Ltd. acquired Shandong Sinobioway Biomedicine Co., Ltd. from Shenzhen Sandao Investment Management Enterprise (Limited Partnership) for CNY 200 million.
September 17, 2021
Share
Xiamen Hengxing Group Co., Ltd. acquired Shandong Sinobioway Biomedicine Co., Ltd. (SZSE:002581) from Shenzhen Sandao Investment Management Enterprise (Limited Partnership) for CNY 200 million on August 10, 2021. As per terms, Xiamen Hengxing Group Co., Ltd. acquired 19.9 million shares of Shandong Sinobioway Biomedicine held by Shenzhen Sandao Investment Management in an Auction conducted by People’s Court of Haidian District of Beijing on the JD Network Judicial Auction Platform from 12:00 on June 11, 2021 to 12:00 on August 10, 2021.
Xiamen Hengxing Group Co., Ltd. completed the acquisition of Shandong Sinobioway Biomedicine Co., Ltd. (SZSE:002581) from Shenzhen Sandao Investment Management Enterprise (Limited Partnership) on August 10, 2021.
Shandong Sinobioway Biomedicine Co Ltd, formerly Zibo Wanchang Science & Technology Co Ltd, is a China-based company principally engaged in the manufacturing of pharmaceuticals. The Company is engaged in the business of interferon, nerve growth factor, biopharmaceutical contract research organization (CRO)/pharmaceutical contract development and manufacturing enterprise (CDMO), vaccines and pharmaceutical intermediates. The Company's main products include anferon, encyclopedia, Corona Virus Disease2019 vaccine and others. The Company distributes its products within domestic market.
SHANDONG SINOBIOWAY BIOMEDICINE CO., LTD. 
